Evidence map›Paper›PMID 33859996›Full record

ArticleFrontiers in molecular biosciences2021

Fabrication of Non-phospholipid Liposomal Nanocarrier for Sustained-Release of the Fungicide Cymoxanil.

Zheng Zhang, Jun Yang, Qing Yang, Guangyong Tian, Zhong-Kai Cui

Abstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zheng ZhangState Key Laboratory for Biology of Plant Diseases and Insect Pests, School of Bioengineering, Dalian University of Technology, Dalian, China.
Jun YangState Key Laboratory for Biology of Plant Diseases and Insect Pests, School of Bioengineering, Dalian University of Technology, Dalian, China.
Qing YangState Key Laboratory for Biology of Plant Diseases and Insect Pests, School of Bioengineering, Dalian University of Technology, Dalian, China.
Guangyong TianGuangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, Southern Medical University, Guangzhou, China.
Zhong-Kai CuiGuangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liposome nanocarriers can be used to solve problems of pesticide instability, rapid degradation and a short period of efficacy. Cymoxanil with antifungal activity requires an ideal drug loading system due to its degradation issues. In this paper, cholesterol and stearylamine were used to prepare non-phospholipid liposomes (sterosomes) as a pesticide nanocarrier, and were characterized with field emission scanning electron microscopy (FE-SEM), X-ray powder diffraction (XRD), Fourier-transform infrared (FT-IR) spectrometer, size distribution, and ζ-potential. The results showed sterosomes were successfully loaded with cymoxanil. The loading efficiency and the drug-to-lipid ratio were 92.6% and 0.0761, respectively. Prolonged drug release was obtained for 3 days, improving the short duration of the drug itself. The addition of cymoxanil-loaded sterosomes in culture medium effectively inhibited the growth of yeast cells, which serve as model fungal targets. Sterosomes as nanocarriers significantly improved the stability and efficacy of cymoxanil, thus introducing practical and economically desirable strategies for the preparation of novel pesticide formulations.

Indexed as

cymoxanilfungicidenanotechnology applicationsnon-phospholipid liposomessustained release

Identifiers

PMID33859996
PMCPMC8042373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.